Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

G20 Health Threats Fund Needs More Clout, WHO’s C-TAP Underused

Executive Summary

Numerous initiatives are under way to maximize equitable access to COVID-19 products around the world, but most have some drawbacks that need to be addressed if they are to meet their goals, according to the medicines access NGO, WEMOS.

You may also be interested in...



Preparing for COVID 2.0: Understanding Animal ‘Spillover’ And Addressing Excessive Nationalism

Former Merck executive Julie Gerberding, Biocon chief Kiran Mazumdar-Shaw, ModeX Therapeutics’ John Mascola, and NIH’s Larry Tabak discuss what it will take to better handle the next pandemic.

COVAX & Team Europe ‘Not Structural Solutions’ To COVID-19 Vaccine Inequity

The medicines access organization, WEMOS, says that COVAX and “Team Europe” are welcome initiatives but they do not address the longer-term issues involved in making countries more self-sufficient in COVID-19 vaccine manufacturing. The organization has set up a website to analyze the various initiatives under way to make vaccines available to less wealthy countries.

Global Summit Hears Pledges To Cut Pandemic Vaccine Development Times

Is a 100-day timeline for developing vaccines against newly identified health threats a realistic proposition? Attendees at this week’s Global Pandemic Preparedness Summit certainly think so. Meanwhile, Moderna has said it will build its first African mRNA plant in Kenya, and has pledged “never” to enforce its vaccine patents in lower-income countries.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS145860

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel